-
Mashup Score: 6Association between country of birth and gastric intestinal metaplasia: a retrospective cohort study - 5 month(s) ago
As a precursor to gastric cancer, gastric intestinal metaplasia (GIM) represents a target for surveillance. US-based guidelines recommend surveillance…
Source: www.sciencedirect.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Cancer of the Stomach - Cancer Stat Facts - 6 month(s) ago
Stomach Cancer statistics
Source: seer.cancer.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Among women, Hispanics have the highest rate of new #StomachCancer cases. The rate of new cases for Hispanic men is higher than the average rate across all racial and ethnic groups. Visit our Cancer Stat Facts sheet to learn more: https://t.co/5G2BXqpowp #MySalud https://t.co/7jgH58rfS0
-
-
Mashup Score: 1Combination Therapy Improves Quality of Life in Advanced Stomach Cancer, Esophageal Cancer - 6 month(s) ago
Combining an immune checkpoint inhibitor with standard chemotherapy improved quality of life for patients with advanced stomach cancer or esophageal cancer compared to chemotherapy alone, according to recent findings published in The Journal of Clinical Oncology.
Source: news.feinberg.northwestern.eduCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“We have a win-win for patients.” Combining a PD-1 checkpoint inhibitor w/ chemotherapy improved quality of life for patients with advanced #stomachcancer or #esophagealcancer, according to findings from @LurieCancer’s David Cella, PhD, in @JCO_ASCO https://t.co/ZO5LmKQgyl #QoL
-
-
Mashup Score: 0
An AI tool can accurately forecast esophageal and stomach cancer risk well in advance, reshaping the landscape of cancer prevention.
Source: www.oncology-central.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🔬 An AI tool has been found to accurately predict #EsophagealCancer & #StomachCancer risk years before diagnosis. Read more here >>> https://t.co/fuTFZAin1V #ArtificalIntelligence #CancerPrevention
-
-
Mashup Score: 0Cancer of the Stomach - Cancer Stat Facts - 8 month(s) ago
Stomach Cancer statistics
Source: seer.cancer.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Among women, the rate of new #StomachCancer cases is highest for Hispanics among all racial and ethnic groups. The rate of new cases is about 42% higher for Hispanic men compared to Hispanic women. Visit our Cancer Stat Facts sheet to learn more: https://t.co/5G2BXqoQGR #MySalud https://t.co/B1N6V30y6G
-
-
Mashup Score: 0FDA Grants Priority Review to Zolbetuximab for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma - 9 month(s) ago
The FDA has granted a priority review to the biologics license application seeking the approval of zolbetuximab for the first-line treatment of patients with unresectable, locally advanced or metastatic, HER2-negative, gastric or gastroesophageal junction adenocarcinoma whose tumors are Claudin18.2 positive.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The BLA seeking the approval of zolbetuximab for CLDN18.2-positive gastric or GEJ adenocarcinoma is supported by data from the phase 3 SPOTLIGHT and GLOW trials. @US_FDA #stomachcancer #oncology https://t.co/AyCWPnHHTu https://t.co/Vnq6YCeZS1
-
-
Mashup Score: 0FDA Grants Priority Review to Zolbetuximab for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma - 9 month(s) ago
The FDA has granted a priority review to the biologics license application seeking the approval of zolbetuximab for the first-line treatment of patients with unresectable, locally advanced or metastatic, HER2-negative, gastric or gastroesophageal junction adenocarcinoma whose tumors are Claudin18.2 positive.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The @US_FDA granted a priority review to zolbetuximab for the first-line treatment of patients with unresectable, locally advanced or metastatic, HER2-negative, gastric or GEJ adenocarcinoma whose tumors are Claudin18.2 positive. #stomachcancer #oncology https://t.co/vq8DHObE1c
-
-
Mashup Score: 0FDA Grants Priority Review to Zolbetuximab for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma - 10 month(s) ago
The FDA has granted a priority review to the biologics license application seeking the approval of zolbetuximab for the first-line treatment of patients with unresectable, locally advanced or metastatic, HER2-negative, gastric or gastroesophageal junction adenocarcinoma whose tumors are Claudin18.2 positive.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FDA Grants Priority Review to Zolbetuximab for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma #stomachcancer #oncology https://t.co/uyFhbDkSd3
-
-
Mashup Score: 4What Is Stomach Cancer? - 10 month(s) ago
Stomach cancer forms in the cells lining the stomach. Learn how stomach cancer starts and the most common types.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📚 💡 Looking for information on #StomachCancer? Our expert-reviewed summary has been updated. Check it out! https://t.co/1pzXnlEfxu https://t.co/3wGpEhOVKp
-
-
Mashup Score: 0Frontline Pembrolizumab Plus Trastuzumab/Chemo Improves PFS in HER2+ Advanced Gastric or GEJ Adenocarcinoma - 10 month(s) ago
The addition of pembrolizumab to trastuzumab and chemotherapy improved progression-free survival over trastuzumab and chemotherapy alone when used as a frontline regimen in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Pembrolizumab + trastuzumab & chemo improved PFS over trastuzumab and chemotherapy alone when used as a frontline regimen in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. #oncology #stomachcancer https://t.co/UFxHZhRoVD https://t.co/FSSs6qXdBY
-
Country of birth is a key factor in assessing risk for conditions favorable to #stomachCancer development @umiamimedicine https://t.co/1nZ30EKIxs https://t.co/0oMEXdaqOi